Qu Biologics Granted US Patent For Use Of E. Coli To Treat Crohn’s Disease

Qu Biologics Granted US Patent For Use Of E. Coli To Treat Crohn’s Disease
Qu Biologics Inc., a biotechnology firm currently developing Site Specific Immunomodulators (SSIs) to restore regular immune function in a specific targeted diseased organ, recently announced that the United States Patent and Trademark Office issued a U.S. Patent to the company for the utilization of immunotherapies that are collected from components of E. coli with the purpose of treating Crohn’s disease. The patent was issued

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *